Background. Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling methodologies based on silicon-, boron-, and aluminium-\(^{18}\)F chemistry deviate from commonplace bonding of an \(^{18}\)F fluorine atom (\(^{18}\)F) to either an aliphatic or aromatic carbon atom. One method in particular, the silicon-fluoride-acceptor isotopic exchange (SiFA-IE) approach, invalidates a dogma in radiochemistry that has been widely accepted for many years: the inability to obtain radiopharmaceuticals of high specific activity (SA) via simple IE.

Methodology. The most advantageous feature of IE labeling in general is that labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. SiFA-IE chemistry proceeds in dipolar aprotic solvents at room temperature and below, entirely avoiding the formation of radioactive side products during the IE. Scope of Review. A great plethora of different SiFa species have been reported in the literature ranging from small prosthetic groups and other compounds of low molecular weight to labeled peptides and most recently affibody molecules. Conclusions. The literature over the last years (from 2006 to 2014) shows unambiguously that SiFA-IE and other silicon-based fluoride acceptor strategies relying on \(^{18}\)F leaving group substitutions have the potential to become a valuable addition to radiochemistry.
the position of the label itself. With the contingent of existing labeling methods, it is possible to label nearly all compounds in sufficient radiochemical yields (RCYs); however, sometimes the required great technical effort can prevent clinical routine production. Currently, only radiochemistries based on coordinating radiometals such as technetium-99m (\(^{99m}\)Tc), which accounts for the majority of all radiopharmaceuticals produced for single-photon emission computed tomography (SPECT), as well as indium-111 (\(^{111}\)In, for SPECT), gallium-68 (\(^{68}\)Ga), and copper-64 (\(^{64}\)Cu) both for positron emission tomography (PET) proceeds in a kit-like manner [1–4]. In particular, \(^{99m}\)Tc radiochemistry evolved over decades into fully GMP compliant (Good Manufacturing Practice) labeling kits where a simple addition of the radionuclide in the chemical form of its pertechnetate (\(^{99m}\)TcO\(_4^−\)) followed by very few simple steps yields the tracer. For other radiometals, final HPLC purification is sometimes inevitable and the operators in the laboratory have to possess a certain degree of technical proficiency and equipment in order to deliver an injectable solution that complies with GMP regulations.

Additional obstacles exist for radiolabeling with the most extensively used PET isotope \(^{18}\)F. The interest towards the development of \(^{18}\)F-radiopharmaceuticals ensues essentially from the low positron energy (635 KeV) and the most suitable half-life (109.7 min) of this radioisotope. As a consequence, \(^{18}\)F is ideal for numerous PET imaging applications involving tracers of low molecular weight as well as various biomolecules with a suitable kinetic profile. In particular, the successful and widespread use of [\(^{18}\)F]2-fluoro-2-deoxy-D-glucose ([\(^{18}\)F]FDG) has ignited the interest in new \(^{18}\)F-tracers but despite its favorable nuclear properties, \(^{18}\)F-radiochemistry remains often associated with relatively cumbersome and lengthy labeling procedures. Indeed, \(^{18}\)F-labeling normally involves relatively large precursor quantities and often requires high reaction temperatures as well as the presence of activating reagents (e.g., strong bases plus cryptands) leading to unwanted radioactive and chemical side products, which need to be thoroughly separated from the desired \(^{18}\)F-labeled tracer. Consequently, there are only few examples published in the literature where the radiochemical labeling procedure does not require a final HPLC purification. This is problematic due to the need for fully GMP compliant synthesis modules, which led manufacturers to search for solid phase based purifications to circumvent HPLC procedures [5–7]. Moreover, the classical use of harsh reaction conditions precludes a direct \(^{18}\)F-radiolabeling of complex biomolecules not able to withstand those reaction conditions. In such cases, the use of \(^{18}\)F-carbon-based prosthetic groups is often necessary, imposing further equipment challenges in addition to the time-consuming aspects.

The recent development of comparatively simple, efficient, and innovative labeling approaches based on silicon-\(^{18}\)F [5, 8–10] and boron-\(^{18}\)F [11–14] bond formation as well as aluminium-\(^{18}\)F [14–19] chelation scaffolds each address in part some of the major drawbacks associated with conventional nucleophilic \(^{18}\)F-labeling on a carbon atom. Particularly, silicon-\(^{18}\)F labeling methods have been increasingly exploited in recent years due to their inherent simplicity and efficiency compared to conventional labeling strategies. The organosilicon-based fluoride acceptor (SiFA) \(^{18}\)F-labeling strategy was initially coined in reference to the isotopic exchange (IE) approach introduced by Schirrmacher et al. [5] (Scheme 1). A more inclusive definition of SiFAs also comprises the alkoxyysilane leaving group approach introduced by Choudhry et al. [20] which was expanded to hydrosilanes and silylols by the group of Ametamey [21]. The current review will detail and discuss the technical developments and applications which have led to the current status of \(^{18}\)F-SiFA radiochemistry as a simplified approach towards new radiopharmaceuticals for PET imaging.

2. SiFA Labeling Chemistry

Formation of Si–F bonds is driven by the strong affinity between silicon and fluorine as exemplified by the high
corresponding bond energy (565 kJ mol\(^{-1}\) for Si–F versus 485 kJ mol\(^{-1}\) for C–F and 318 kJ mol\(^{-1}\) for Si–C). Simple organofluorosilanes display poor kinetic stability and may be cleaved under mild conditions in the presence of fluoride or other silophiles due to the high polarization of Si–F bonds which is also true for Si–O bonds. Tetravalent silicon readily reacts with Lewis bases to form hypervalent species (both 5- and 6-coordinate) as a consequence of vacant low energy d-orbitals. Moreover, the greater covalent radius of silicon versus carbon contributes to the enhanced propensity of organosilanes to undergo nucleophilic substitutions at the silicon atom compared to their carbon-centered counterparts. Those characteristics build the foundation of various nonradioactive organosilicon chemistries and are also central to the development of \(^{19}\text{F}\) organofluorosilanes for PET imaging.

The synthesis of \(^{18}\text{F}\)-labeled silicon tetrafluoride (Si[\(^{18}\text{F}\])F\(_4\)) via metallic hexafluorodisilicate formation from metallic fluorides and SiF\(_2\) has been known for more than half a century in radiochemistry [22–24]. \(^{18}\text{F}\)Fluorotrimethylsilane ([\(^{18}\text{F}\])2] was also reported as a hypothetical intermediate from hexamethylosilane reaction with \(^{18}\text{F}\)HF as early as 1978 [25]. The first in vivo evaluation of silicon-\(^{18}\text{F}\) building blocks was introduced by Rosenthal et al. with the radiosynthesis of the volatile species [\(^{18}\text{F}\)]2] from chlorotrimethylsilane (I; Scheme 1) [26]. The labeling proceeded efficiently delivering [\(^{18}\text{F}\)]2] using no-carrier-added (nca) tetramethylammonium-\(^{18}\text{F}\)fluoride ([\(^{18}\text{F}\])TMAF, 80% radiochemical yield (RCY) decay-corrected); however, upon inhalation by rats extensive bone uptake was observed as a result of defluorination (anionic \(^{18}\text{F}\)– is rapidly taken up by the bone apatite). This result paralleled the observed poor hydrolytic in vitro profile of [\(^{18}\text{F}\)]2] which led the authors at the time to suggest that bulkier groups at the silicon atom may be necessary in order to generate hydrolytically stable \(^{18}\text{F}\)-silicon building blocks. This original contribution was followed by the development of variations of \(^{18}\text{F}\)fluorotrimethylsilane-based release of dry nca \(^{18}\text{F}\) for the use in nucleophilic radiofluorination [27, 28].

In a more recent study, the group of Perrin provided an innovative approach towards \(^{18}\text{F}\)-silicon building blocks, synthesizing the biotin-linked alkyl tetrafluorosilicate [\(^{18}\text{F}\])4 via near-quantitative carrier added radiofluorination (from KH\(_2\)F) [3]. A typical reaction procedure involved reacting alkyl triethoxysilane 3 with a preformed mixture of 440 \(\mu\)Ci of \(^{18}\text{F}\)/H\(_2\)O from target water ([\(^{18}\text{O}\)]H\(_2\)O) along with 130 mM KH\(_2\)F (4.4 equiv.) in 200 mM NaOAc (pH 4.5). This important development also constituted the first efficient \(^{18}\text{F}\)-aqueous labeling and provided, despite hydrolytic stability concerns, the groundwork for \(^{18}\text{F}\)-silicon radiochemistry developments.

In 2006, Schirrmacher et al. convincingly demonstrated that [\(^{18}\text{F}\])SiFA building blocks could be generated in high RCYs and specific activity (SA) by means of a IE from the corresponding- and chemically identical- \(^{19}\text{F}\)-precursors [5]. Conversion of [\(^{19}\text{F}\])tBu\(_2\)PhSiF (5) to the radiolabeled [\(^{18}\text{F}\])tBu\(_2\)PhSiF ([\(^{18}\text{F}\])5) proceeded in 80–95% RCYs in the presence [\(^{18}\text{F}\])/Kryptofix 2.2.2/K\(^{+}\) in acetonitrile (100 \(\mu\)L) with minimal precursor quantity (1 \(\mu\)g). The prototypical di-tert-butyphenyl-bearing SiFA [\(^{18}\text{F}\])5 was obtained in SAs of 2.7–27 Ci\(\mu\)mol\(^{-1}\) and the methodology was also applied to direct, unprotected labeling of SiFA-aminooxy-derivatized Tyr\(^3\)-octreotate at room temperature (see Section 4). This work validated that IE at the silicon atom (SiFA-IE) constitutes an effective and mild methodology towards new \(^{18}\text{F}\)-labeled compounds. The authors also reported an early stability study of a series of labeled SiFA derivatives (vide infra). This result was reported almost simultaneously with the important contribution of Choudhry et al. establishing a silicon-leaving group approach to the radiosynthesis of [\(^{18}\text{F}\])SiFA starting from an alkoxy-substituted acceptor precursor [20]. The reaction proceeded directly from aqueous \(^{18}\text{F}\)– and allowed for the efficient conversion of tert-butyldiphenylmethoxysilane (6) to [\(^{18}\text{F}\])tert-butyldiphenylfluorosilane ([\(^{18}\text{F}\]7) at room temperature in 5 minutes.

The leaving group methodology currently constitutes one of the two extensively exploited strategies towards [\(^{18}\text{F}\])SiFAs—the other one being the SiFA-IE. Both approaches were shown to deliver [\(^{18}\text{F}\])SiFA in high RCYs and SAs (Figure 1(a)). Yet, important distinctions exist between the two techniques, one of which resides in the fact that the IE typically proceeds at room temperature or below while the Si-leaving group approach, like aliphatic and aromatic \(^{18}\text{F}\)-carbon radiochemistry in general, necessitates elevated temperatures which may be detrimental when direct labeling of biomolecules is considered.

The efficiency of the IE, even at low temperatures, can be attributed to the low energy barrier for the \(^{19}\text{F}\)– isoeenergetic replacement with \(^{18}\text{F}\) in acetonitrile via the formation of a trigonal bipyramidal siliconate anion intermediate (\(\Delta G_{\text{IE}} = 0\); negligible isotopic effect; Figure 2). Indeed, DFT calculations in condensed phase (acetofluorite) on model SiFAs of the type R\(_x\)SiF\(_{3}\)– indicated that \(\Delta G\)\(_{\text{f}}\) values associated with the formation of siliconate intermediates from those precursors range from 5 to 10 kcal mol\(^{-1}\) (Figure 1(b), upper path) [29]. On the other hand, in the gas phase, values of \(\Delta G\)\(_{\text{f}}\) of –50 to –40 kcal mol\(^{-1}\) were calculated in agreement with the expected formation of thermodynamically stable organofluorosilicates (Figure 1(b), lower path) [30, 31]. Those energetic differences ensue from the diminished Lewis basicity of the fluoride anion in acetofluorite compared to that in the gas phase, suggesting that in the former case equilibrium is rapidly reached leading to the fast and near-reversible formation of [\(^{18}\text{F}\])SiFA species as a consequence of stoichiometric leverage. Kostikov et al. also experimentally determined a characteristic low activation energy \(E_a = 15.7\) kcal mol\(^{-1}\) and exceptionally low preexponential factor \((A = 7.9\times10^{13} \text{ M}^{-1} \text{ s}^{-1})\) for the SiFA-IE from the corresponding Arrhenius plot [32]. These results are in contrast with the values gained from a comparable carbon-\(^{18}\text{F}\) bond formation reaction, namely, the \(^{18}\text{F}\)-fluorination of ethyleneglycol-di-p-tosylate \((E_a = 17.0\) kcal mol\(^{-1}\) and \(A = 2.9\times10^9 \text{ M}^{-1} \text{ s}^{-1})\), and support the experimental observation that SiFA-IE
proceeds quasi-quantitatively in many instances even at low temperatures [32]. In contrast, $^{18}$F-radiofluorination of more stable silanol precursors [33] (or other leaving group bearing silanes) should be endergonic ($\Delta G > 0$) and associated with less stable hydrosiliconate intermediates in both gaseous and condense phases as expected from bond dissociation energies (BDEs).

An additional important distinction between IE and the leaving group method relates to purification techniques. Since the IE involves chemically identical entities and proceeds under mild conditions that do not lead to side products, HPLC purification can often be avoided and purification can be limited to solid phase cartridge extraction (SPE). This approach is feasible irrespective of the nature of the tracer (e.g., small fragments or biomolecules). In contrast, HPLC purification constitutes a prerequisite of the leaving group approach as chemically distinct precursors and $^{18}$F-radiolabeled products have to be carefully separated.

Nevertheless, this method has been thoroughly developed and adapted frequently by the radiochemistry community. Since the initial contribution of Choudhry et al., the group of Ametamey and coworkers has further extended the silicon-leaving group approach methodology to hydride, hydroxy, and alkoxy leaving groups.

Mu et al. exemplified this method with the radiosynthesis of a series of fluorosilanes bearing alkyl ($[^{18}$F]$^{10}$, $[^{18}$F]$^{11}$) or aryl ($[^{18}$F]$^{15}$, $[^{18}$F]$^{16}$) Si-linked fragments containing various R groups (Scheme 2) [21]. Few compounds such as the dimethyl- (8) and diisopropylethoxysilane (9) reacted readily at 30°C whereas most substrates necessitated elevated temperatures ($65^\circ\text{-}90^\circ\text{C}$) in order to react with the $^{18}$F$^{-}$. Compounds $[^{18}$F]$^{15}$ and $[^{18}$F]$^{16}$ were obtained in moderate to high RCYs from the corresponding silanol and silanes (SA of $[^{18}$F]$^{16}$ = 1.73 Ci $\mu$mol$^{-1}$). As expected, adding acetic acid significantly influenced incorporation yields in the presence...
of O-bearing leaving groups but did not modify hydride rate
departure from precursor 13.

In a recent study, the leaving group SiFA methodology
was combined with the nucleophile assisting leaving
group (NALG) strategy to generate Si-appended potassium-
chelating SiFA-based leaving groups [34, 35]. In the absence
of added Kryptofix 2.2.2, the facilitation of 18F-fluorination
in the presence of cyclic crown ethers such as in 17 compared
to acyclic polyethers or alkoxide leaving groups was clearly
established. Unfortunately, the RCYs were undermined by
the limited solubility (1-5%) of nca K18F in the reaction
media. This issue was partially addressed by water addition
(up to 0.5% v/v) leading to an increased K18F solubility (31%),
but further addition subsequently diminished the observed
RCYs. Consequently, upon optimized conditions, [18F]7
was obtained in overall 10% RCY (Scheme 3). Thus, despite being
costucturally elegant and promising, this approach is signifi-
cantly hampered by 18F solubility issues which will possibly
be addressed in the future to establish this methodology as a
practical alternative to the simpler and straightforward SiFA-
leaving group method or IE methodology.

3. SiFA Lipophilicity and Hydrolytic Stability

Stability investigations of a series of phenyl- and tert-butyl-
bearing [18F]SiFAs ([18F]5, [18F]7, and [18F]18) early on
established the importance of the tert-butyl substituents
at the silicon atom in order to achieve sufficient in vivo
stability for potential in vivo PET applications (Figure 3)
[5]. Compound [18F]18 displayed poor in vitro stability
in human serum at 37.4°C (t1/2 = 5 min) while both
[18F]5 and [18F]7 were found to be persistently stable under
those conditions. However, only [18F]-tBu2PhSiF ([18F]5)
showed satisfactory in vivo stability as demonstrated by
the limited 18F bone uptake observed upon injection into
Sprague Dawley rats. The stability trend originates from steric
hindrance in combination with the diminished silicon Lewis
acidity in the presence of tert-butyl fragments. Unfortunately,
this substitution pattern comes at the price of a significant
increase in lipophilicity which, when chemically linked to
biomolecules, may substantially impact metabolism and
biodistribution, generating unspecific uptake and leading to
poor PET imaging quality. This issue has been addressed by
Further confirmation of the importance of sterically demanding SiFA substituents was provided by the detailed and systematic investigation on hydrolytic stability led by Höhne et al. (Table 1) [33]. The observed trends strongly correlate with the steric nature of the silicon substituents. In particular, the presence of bulky tert-butyl groups, combined with an aryl linker moiety, result in remarkable stability whereas smaller alkyl substituents progressively enhance the hydrolysis rate. Furthermore, the authors also provided a detailed hydrolysis mechanism (Scheme 4) as well as a theoretical model based on the difference in Si–F bond lengths (Δ(Si–F)) between the starting SiFA structures (A) and the DFT optimized intermediate structure (D) (where Δ(Si–F) ≥ 0.19 Å corresponds to hydrolytically unstable SiFAs).

4. [18F]SiFA Labeling of Peptides

The labelling of peptides for PET imaging has traditionally been achieved via multistep strategies involving [18F]-labeled prosthetic groups. This strategy succeeded in generating multiple peptide-based...
| Cpd | Structure | $t_{1/2}$ (h) | Reference |
|-----|-----------|--------------|-----------|
| 10  | ![Structure_10](image) | 0.08<sup>a</sup> | [33] |
| 19  | ![Structure_19](image) | 0.1<sup>a</sup> | [33] |
| 20  | ![Structure_20](image) | 8<sup>a</sup> | [33] |
| 11  | ![Structure_11](image) | 12<sup>a</sup> | [33] |
| 21  | ![Structure_21](image) | 15<sup>a</sup> | [33] |
| 22  | ![Structure_22](image) | 21<sup>a</sup> | [33] |
| 23  | ![Structure_23](image) | 29<sup>a</sup> | [33] |
| 24  | ![Structure_24](image) | 37<sup>a</sup> | [33] |
| 25  | ![Structure_25](image) | 37<sup>a</sup> | [33] |
| 26  | ![Structure_26](image) | 43<sup>a</sup> | [33] |
| 27  | ![Structure_27](image) | 61<sup>a</sup> | [33] |
| 28  | ![Structure_28](image) | 79<sup>a</sup> | [33] |
| Cpd | Structure | $t_{1/2}$ (h) | Reference |
|-----|-----------|-------------|-----------|
| 29  | ![Structure 29](image) | 302$^a$ | [33] |
| 30  | ![Structure 30](image) | $>300^a$ | [33] |
| 16  | ![Structure 16](image) | $>300^a$ | [33] |
| 31  | ![Structure 31](image) | 8$^b$ | [36] |
| 32  | ![Structure 32](image) | 16$^b$ | [36] |
| 33  | ![Structure 33](image) | $>>2^c$ | [32] |

$^a$Hydrolytic stability determination from nonradioactive compounds in MeCN/aqueous buffer (2:1; pH 7) at room temperature. $^b$Hydrolytic stability determination from $^{18}$F-labeled compounds in EtOH/aqueous buffer at room temperature. $^c$95% intact after 2 h of incubation; hydrolytic stability determination from $^{18}$F-labeled compounds at pH 7.4.

Figure 4 presents various synthesized SiFA building blocks bearing reactive groups for peptide conjugation (for proteins and small molecules *vide infra*) [6, 32, 41–45]. The coupling of those SiFAs to peptides prior to the IE labeling would in theory allow for a direct and mild $^{18}$F-incorporation without subsequent HPLC purification. Indeed, this was early demonstrated by Schirrmacher et al. [5] with the direct radiosynthesis of $[^{18}$F]SiFA-derivatized Tyr$^5$-octreotate ($[^{18}$F]50, Scheme 6). Despite the unprecedented mild conditions encountered and the high $^{18}$F-fluorination
efficiency of 95–97% and 57–66% isolated RCYs (nondecay corrected), the approach suffered from low SAs (0.08–0.14 Ci/mmol).

Subsequently, a two-step procedure which consists of the near quantitative initial fluorination of the aldehyde $^{18}$F$^37$ (Scheme 7) in high SAs (>5000 Ci/mmol), followed by a rapid C-18 SPE purification and subsequent room temperature conjugation to $N$-terminal amino-oxy functionalized Tyr$^3$-octreotate, was reported [29] (Table 2 recapitulates selected examples of SiFA-peptide labeling). In the same study, the $^{18}$F$^37$ synthon was also efficiently applied to the labeling of a cyclic RGD (Arg-Gly-Asp) and a PEG-conjugated bombesin (BBN) analogue (cyclo(FK(AO-N)RGD and BZH3, resp.).

In parallel, important progress towards the direct fluorination of bioactive peptides from hydrosilanes and silanol precursors following the leaving group approach was made. The initial report by Mu et al. illustrates the methodology with the synthesis of two $^{18}$F$^37$-labeled tetrapeptides. The reactions proceeded at 65–90°C with moderate incorporation of $^{18}$F from either of the hydrosilane and the silanol (45% and 53%,
### Table 2: Structure of selected $^{18}$F-silicon-based derivatives attached to different peptide ligands and their appended linkers and lipophilicity-reducing auxiliaries.

| Entry | Labeled peptide | Labeling method$^{a}$/SA/purification method/RCY$^{b}$ | Reference |
|-------|----------------|------------------------------------------------------|-----------|
| 1     | Octreotate analogues | Direct IE/0.08–0.14 Ci $\mu$mol$^{-1}$/C-18 SPE/55–65% eos | [5]       |
|       | cRGD | Prosthetic IE/6.1–18.4 Ci $\mu$mol$^{-1}$/HPLC/50–55% eos | [29]     |
| 2     | Bombesin analogues | Prosthetic IE/6.1–18.4 Ci $\mu$mol$^{-1}$/HPLC/50–55% eos | [29]     |
| 3     | Octreotate analogues | Direct IE/0.78–1.5 Ci $\mu$mol$^{-1}$ (18.4 Ci $\mu$mol$^{-1}$ for prosthetic IE)/C-18 SPE/38 ± 4% eos | [47]     |
| 4     | Octreotate analogues | Direct IE/0.78–1.5 Ci $\mu$mol$^{-1}$ (18.4 Ci $\mu$mol$^{-1}$ for prosthetic IE)/C-18 SPE/38 ± 4% eos | [47]     |
| 5     | Octreotate analogues | Direct IE/1.30 Ci $\mu$mol$^{-1}$/C-18 SPE/34% eos | [41]     |
| 6     | Octreotate analogues | Direct IE/1.30 Ci $\mu$mol$^{-1}$/C-18 SPE/70% eos ($n = 1$) | [41]     |
Table 2: Continued.

| Entry | Structure | Bombesin analogues | Direct from silanol/ hydrosilane/ HPLC | Radiochemical yield |
|-------|-----------|--------------------|----------------------------------------|-------------------|
| 7     | ![Structure 7](image) | ![Structure 7](image) | Direct from silanol/ hydrosilane/ HPLC | ![Radiochemical yield 7](image) |
| 8     | ![Structure 8](image) | ![Structure 8](image) | Direct from hydrosilane/ HPLC | ![Radiochemical yield 8](image) |
| 9     | ![Structure 9](image) | ![Structure 9](image) | Direct from hydrosilane/ HPLC | ![Radiochemical yield 9](image) |
| 10    | ![Structure 10](image) | ![Structure 10](image) | Direct from hydrosilane/ HPLC | ![Radiochemical yield 10](image) |

*Via isotopic exchange (IE) either direct or in two steps or via the leaving group approach from the specified precursor. The RCYs are reported as isolated end of synthesis (eos) yields either decay correct (dc) or not (ndc); in the absence of available RCYs at eos, incorporation RCYs are reported.

resp.) [21]. The importance of the bulky t-Bu₂Ph-SiFA motif to guarantee hydrolytic stability was confirmed once more. Both an iPr₂Ph-SiFA bombesin analogue [33] and two alkyl-linked iPr₂-SiFA model triptides were shown to be unstable (pH 7.5, phosphate buffer) [46] (Figure 5). Following the leaving group approach, the development and first in vivo evaluation of a [¹⁸F]SiFA labeled bombesin analogue in PC3 xenografted nude mice were subsequently reported [9, 33] (Table 2; Entry 7). The authors reported low uptake in gastrin-releasing peptide receptor (GRP) positive tumor bearing mice and high unspecific binding along with prominent hepatobiliary excretion, despite sufficient potency (IC₅₀ = 22.9 nM) based on comparison with previously characterized successfully radiolabeled BBN analogues. The observation of gradually increasing but overall low bone uptake suggested that di-tert-butyl aryl [¹⁸F]SiFA was sufficiently stable in vivo. Hence, the poor pharmacokinetic profile observed was reasonably ascribed to the overall high lipophilicity of the probe imparted by the SiFA moiety.

Wängler et al. reported the synthesis, HPLC-free purification, and in vivo evaluation of carbohydrate and carbohydrate/PEG derivatized [¹⁸F]SiFA-octreotate probes for imaging sst2-expressing tumors (AR42J xenografts; Table 2; Entries 3 and 4). [47]. This study, based on the previously successful use of hydrophilic linkers for enhanced tumor uptake and optimized excretion of PET/SPECT imaging peptides introduced by Schottelius and Antunes et al. [48–50], established the efficiency of peptide SiFA derivatives

![](image) **Figure 5:** Hydrolytically unstable di-iPr-SiFAs triptides reported by Balentova et al.
with lipophilicity-reducing auxiliaries as a potential strategy for optimized PET imaging. The in vivo investigation of the most promising PEG/glucose-linked derivative ([\(^{18}\)F]SiFA-Asn(AcNH-β-GIc)-PEG-Tyr\(^3\)-octreotate - IC\(_{50}\)(sst2) = 3.3 ± 0.3 nM; Table 2, Entry 4) showed enhanced tumor uptake (7.7% ID/g at 60 min p.i.) compared to the initial negligibly accumulating [\(^{18}\)F]-SiFA-Tyr\(^3\)-octreotate (entry 1). This positive, yet still nonoptimal result was attributed to the improved hydrophilicity of the probe (log \(D_{\alpha,\beta}\) = 0.96 versus 1.59 for [\(^{18}\)F]-SiFA-Tyr\(^3\)-octreotate) and encouraged the introduction of hydrophilic auxiliaries as a promising lipophilicity counterbalancing strategy for SiFA-peptide probe development. This approach has since been translated into a general procedure aiming at the modular cartridge-based radiosynthesis of various [\(^{18}\)F]SiFA peptides in conjunction with lipophilicity-reducing auxiliaries [51].

Two recent additional studies described further lipophilicity reducing auxiliaries for SiFA-peptides. Firstly, Amigues et al. introduced a PEG/ribose [\(^{18}\)F]-SiFA-RGD probe ([\(^{18}\)F]SiFA-RiboRGD; Table 2, Entry 8) as a silicon-based alternative with counterbalanced lipophilicity to the well-known [\(^{18}\)F]Galacto-RGD [52, 53]. [\(^{18}\)F]SiFA-RiboRGD was obtained from the corresponding hydrosilane in satisfactory yields and SA (Table 2) and the in vivo PET evaluation suggested that the tracer might be useful in the determination of \(\alpha\)v\(\beta\)3 integrin expression as significant tumor uptake was reported.

Secondly, the group of Ametamey introduced another lipophilicity reducing strategy towards the development of optimized [\(^{18}\)F]SiFA bombesin analogues [36]. The synthesis of tartaric acid/l-cysteic acid-containing linked BBN derivatives allowed for a significant lipophilicity reduction (log \(D_{\alpha,\beta}\) = 0.3 ± 0.1 for [\(^{18}\)F]54 versus 1.3 ± 0.1 for cysteic acid free peptide-entry 7, Table 2). The in vivo evaluation of the most potent derivative [\(^{18}\)F]54, which was labeled in low overall RCY of 1.8% from the hydrosilane 53, demonstrated that the positive physicochemical alteration introduced by the hydrophilic auxiliary correlated with improved imaging properties (Scheme 8). Enhanced tumor accumulation and tumor-to-blood ratio were detected in PC-3 xenografted mice compared to the lipophilic [\(^{18}\)F]SiFA-BBN probe.

5. [\(^{18}\)F]SiFA Protein Labeling

The [\(^{18}\)F] labeling of large biomolecules, such as proteins, antibodies, and more recently affibodies, has traditionally been accomplished by [\(^{18}\)F]-carbon prosthetic labeling agents such as [\(^{18}\)F]fluorobenzaldehyde ([\(^{18}\)F]FBA), N-(2-[4-(\(^{18}\)F)fluorobenzamido]ethyl)maleimide ([\(^{18}\)F]FBEM), and N-succinimidyl 4-[\(^{18}\)F]fluorobenzoate ([\(^{18}\)F]SFB) [54–57]. Notwithstanding successful conjugation of those prosthetic groups to various proteins, their conjugation normally requires multiple hours of technical manipulations from the initial [\(^{18}\)F]− drying to the delivery of the labeled proteins. SiFA-IE, which proceeds rapidly and efficiently under mild conditions, offers much simplified procedures towards [\(^{18}\)F]-labeled proteins.

Initial attempts to radiolabel active esters such as N-succinimidyl 3-(di-tert-butyl[\(^{18}\)F]fluorosilyl)benzoate 46 ([\(^{18}\)F]SiFB) and the pentafluorophenyl ester 47 for protein labeling failed even under IE conditions due to the propensity...
of those reactive moieties to hydrolyze under even slightly basic conditions. As an alternative approach, Iovkova et al. designed a prefunctionalization strategy involving protein derivatization with 2-iminithiolane (57) followed by the reaction with the SiFA maleimide \( [^{18}\text{F}]45 \) for the labeling of rat serum albumin (RSA) used for blood pool PET imaging (Scheme 9) [45]. The derivatization strategy was also applied with success to RSA labeling with \([^{18}\text{F}]\text{SiFA-SH}\) (\([^{18}\text{F}]38\)) [6]. Protein functionalization with sulfo-SMCC (55) followed by treatment with \([^{18}\text{F}]\text{SiFA-SH}\) obtained by IE allowed for the isolation of \([^{18}\text{F}]\text{SiFA-RSA}\) in overall 12% RCY within 20–30 minutes. An important improvement towards simplified labeling was reported by Rosa-Neto et al. with the first introduction of a direct labeling agent, \([^{18}\text{F}]\text{SiFA-isothiocyanate}\) (\([^{18}\text{F}]41\)) which obviates preceding protein derivatization [44]. Remarkably, and despite the high reactivity of the isothiocyanate fragment, the IE proceeded nearly in quantitative yields (95% RCY; rt; 10 min) and allowed for the efficient direct synthesis of various \([^{18}\text{F}]\)-labeled model proteins (RSA, apotransferrin, and bovine IgG) in suitable SAs (2.7–4.5 Ci \( \mu \text{mol}^{-1} \)).

Subsequently, the decomposition of active esters such as \([^{18}\text{F}]\text{SiFB}\) (\([^{18}\text{F}]46\)) during radiolabeling due to the basicity of the reaction mixture (potassium oxalate/hydroxide) was resolved by addition of a suitable amount of oxalic acid in order to neutralize the base present during the labeling procedure [42]. This study showed the feasibility of the cartridge-based synthesis of \([^{18}\text{F}]\text{SiFB}\) and demonstrated the applicability of this labeling synthon for protein labeling. This new SiFA-based approach is technically much less demanding than the radiosynthesis of the well-known \( N\)-succinimidyl 4-\(|^{18}\text{F}|\)fluorobenzoate (\(|^{18}\text{F}|\text{SFB}\) ), providing a simple access to \(^{18}\text{F}\)-labeled proteins. This has led to the report of a standardized protocol for protein labeling via SiFB [58]. A straightforward labeling protocol has also been reported for protein labeling with \([^{18}\text{F}]\text{SiFA-SH}\) (\([^{18}\text{F}]38\)) [59].

The scope of SiFA-IE has recently been extended to the labeling of affibodies. Glaser et al. reported the efficient synthesis of a cysteine modified human epidermal growth factor receptor (HER2)-targeted affibody, \([^{18}\text{F}]Z_{\text{HER2,2891}}-\text{Cys-SiFA}\) (Scheme 10) [60]. This study demonstrated the convenience and selectivity of the IE at a silicon-atom with the efficient aqueous radiolabeling of \([^{18}\text{F}]Z_{\text{HER2,2891}}-\text{Cys-SiFA}\) precursor from \([^{18}\text{F}]F-\text{/}[^{18}\text{O}]\text{H}_{2}\text{O}\). Similar procedures had previously been described for the synthesis of a small SiFA-octreotate derivative (Scheme 7, \([^{18}\text{F}]50\)) by Schirrmacher et al. [5]; however, direct aqueous labeling of large biomolecules such as affibodies (58 amino acids) is remarkable. Comparison with \([^{18}\text{F}]\)benzaldehyde (\([^{18}\text{F}]\text{-FBA}\) and \([^{18}\text{F}]\text{Al-F/NOTA}\) protocols conclusively demonstrated the efficiency of the SiFA-IE technique in terms of synthesis (RCYs, purity, and SA) despite an observed inferior in vivo profile, mainly attributed to hydrolysis leading to \(^{18}\text{F}\) bone uptake.

6. Towards a Kit Formulation for SiFA-IE

Recently, a new drying method known as the “Munich method” has been introduced by Wessmann et al. which
significantly simplified $^{18}$F radiochemistry compared to the more classical and time-consuming azeotropic drying of $^{18}$F- [61]. The technique consists of the elution of dry $^{18}$F from an anion exchange cartridge (SAX) with lyophilized Kryptofix 2.2.2./potassium hydroxide complex dissolved in anhydrous acetonitrile (Figure 6).

This procedure is fast (3–5 min) and fully devoid of azeotropic drying and is easily implemented into an automated setup. The recent implementation of the “Munich method” alongside the SiFA-IE labeling approach for peptide and protein labeling [43, 46, 58, 59] offers unique and unequaled simplicity, where, starting from commercially available $[^{18}\text{F}]\text{F}^-/[^{18}\text{O}]\text{H}_2\text{O}$, it is possible to deliver $[^{18}\text{F}]\text{SiFA}$ radiopharmaceuticals using only room temperature transformations and facile cartridge-based manipulations. Following this approach, the $^{18}$F-labeling of complex unprotected biomolecules becomes almost as easy as using a $^{99}$m-Tc-kit.

### Figure 6: Combination of SiFA-IE strategy with the “Munich” $^{18}$F drying method. The combination of the “Munich method” and the simple cartridge purification achievable by IE allows for a simple kit production procedure.

#### Scheme 10: Aqueous IE radiosynthesis of $[^{18}\text{F}]-Z_{\text{HER2,2891}}$-Cys-SiFA by Glaser et al.

### 7. Small Molecules

It has previously been shown that, in the absence of suitable auxiliaries, the intrinsic lipophilicity introduced by the SiFA moiety often results in significant alteration of the overall physicochemical properties and in vivo biodistribution of the bioactive compound to which they are bound. This is especially true for ligands with low molecular weight. Nevertheless, certain groups have studied $^{18}$F-radiolabeled silicon-based small ligands for PET imaging and, in some cases, obtained preliminary useful in vivo PET data.

An initial study by Bohn et al. and a follow-up investigation by Joyard et al. demonstrated the synthesis, radiolabeling, and in vivo evaluation of silicon-based analogues of $[^{18}\text{F}]\text{FMISO}$, an established tracer for detection of hypoxia [62, 63]. In spite of the well-known steric requirements of the silicon atom, the authors described a series of alkyl substituted $[^{18}\text{F}]\text{SiFA}$-FMISO analogues which resulted in insufficient hydrolytic stability both in vitro and in vivo (Table 3; Entries 1 and 2). Accordingly, the dimethyl $[^{18}\text{F}]$SiFA MISO compound ($t_{1/2} < 5 \text{ min}$) only showed poor tumor uptake in mice while radioactivity accumulation occurred rapidly and significantly in bones due to the in vivo liberation of $^{18}$F$^-$. The more stable dinaphthyl derivative ($t_{1/2} = 125 \text{ min}$) (Entry 4, Table 3) was retained in pulmonary capillaries due to its high lipophilicity (cLog P = 6.47). After evaluating other unstable derivatives, the authors described the synthesis and evaluation of a promising $\beta\text{Bu}$-Ph-based $[^{18}\text{F}]\text{SiFA}$ tracer (Entry 7, Table 3) which was sufficiently stable for in vivo PET evaluations in rat. Upon injection, the tracer was shown to be heterogeneously distributed in healthy rats but unfortunately no evaluation in animals bearing a hypoxic tumor was reported.

Recently, Schulz et al. reported a protocol for the efficient radiolabeling of nucleosides and nucleotides derivatized with the SiFA building block. The labeled silylated thymidines $[^{18}\text{F}]\text{58}$ and $[^{18}\text{F}]\text{59}$ were obtained in high SA (10 Ci $\mu$mol$^{-1}$) from the corresponding hydrosilanes in 43% and 34% RCYs, respectively (Figure 7) [64]. Despite the potential application of those SiFA tracers as $[^{18}\text{F}]\text{FLT surrogate}$s, no in vivo data is
Table 3: Structures of $^{18}$F-silicon-based nitroimidazoles for PET hypoxia imaging.

| Entry | R$^a$ | Reference |
|-------|-------|------------|
| 1     | Me$^1$ $^{18}$F Me | [62] |
| 2     | i-Pr$^1$ $^{18}$F i-Pr | [62] |
| 3     | Ph $^{18}$F Ph | [62] |
| 4     | | [62] |
| 5     | | [63] |
| 6     | | [63] |
| 7     | | [63] |

$^a$Tracers were obtained via the SiFA leaving group approach from the corresponding silyl ethers.

Currently available. The described procedure was also applied to the $^{18}$F-radiolabeling of di- and oligonucleotide probes.

In a thorough study, silicon-based $D_2$-receptor ligands with structures analogous to $[^{18}F]$fallypride ($[^{18}F]60$) and $[^{18}F]$desmethoxyfallypride ($[^{18}F]61$) were reported (Figure 8) [65]. Derivatization with SiFA resulted in 44–650 times decreased affinities towards the $D_2$-receptor compared to fallypride ($K_i = 0.0965 \pm 0.0153$ nM), yet remaining in the low nanomolar range. Upon optimization, the IE strategy delivered tracers $[^{18}F]62$, $[^{18}F]63$, and $[^{18}F]64$ in 54–61% RCYs and all three tracers could be purified by just using SPE techniques. The measured SAs were in the range of 1.1–2.4 Ci $\mu$mol$^{-1}$. The most potent derivative, $[^{18}F]65$ ($K_i = 4.21 \pm 0.41$ nM), was labeled in only the modest RCY while stability issues prevented its purification following the solid-phase method. In vivo PET data were not reported.
The most recent contribution from Hazari et al. describes the design and evaluation of a highly potent and selective 5-HT₁A homodimeric SiFA-dipropargyl glycerol derivatized radioligand aimed at PET imaging of dimeric serotonin receptors (Figure 9; [¹⁸F]65) [66]. This multimeric approach is supported by the development of bivalent 5-HT ligands based on recent evidence suggesting that some 5-HT receptors exist as dimers/oligomers [67]. The tracer, [¹⁸F]BMPPSiF, was obtained following the leaving group approach from the corresponding hydrosilane. The synthesis of the precursor was achieved via double azide-alkyne Huisgen cycloaddition with two azidoethyl (2-methoxyphenyl)piperazine fragments. Subsequent [¹⁸F]-radiofluorination occurred in 52 ± 10.5% RCY upon heating to yield [¹⁸F]BMPPSiF with a SA of 13 Ci/µmol⁻¹. Brain PET imaging in rats showed high uptake in 5-HT₁A receptor rich regions. As expected, significant reduction of the uptake in the hippocampus was detected in serotonin-depleted rat models. Blocking studies did not reveal significant decrease in uptake. Notably, this report constitutes the first example of a SiFA-small ligand with positive PET imaging data. Interestingly, it also suggests that when applicable, [¹⁸F]SiFA-based multimeric derivatization may help compensate the overall influence on physicochemical parameters of the SiFA moiety on small ligands.

8. SiFA: A Critical Assessment

From the very first appearance of SiFA compounds in 2006 and 2008 the groups of Ametamey and Schirrmacher/Wängler/Jurkschat have put extensive efforts into the structural optimization of the SiFA building blocks. The main drawback of this labeling technique irrespective of the actual labeling methodology (IE or leaving group approach) is the inherently extremely high lipophilicity hampering in vivo application in general. The compounds of the first generation when injected into animals were almost exclusively metabolized by the hepatobiliary system which lead to a high liver uptake and almost zero uptake in the target tissue. Both groups have approached this problem by introducing hydrophilic components into the SiFA tagged molecules to compensate for the high lipophilicity. However, this strategy is only useful for larger biomolecules such as peptides and proteins which tolerate an extensive structural modification. It could be convincingly demonstrated by Niedermoser et al. recently that highly hydrophilic SiFA derivatized somatostatin analogues can be labeled in a one-step reaction via IE in high RCYs and SAs of 1200–1700 Ci/mmol [68]. High IC₅₀ values of the SiFA-peptides in the low nanomolar range and a very high tumor uptake of >15% in a AR42J nude mice tumor model showed that the lipophilicity problem has been successfully solved, paving the way for a human clinical application in the near future. The most recently published paper by Lindner at al. demonstrated that SiFA tagged RGD peptides can serve as tumor imaging agents in a mouse U87MG tumor model if hydrophilic auxiliaries are added in combination with the SiFA labeling moiety [69]. A tumor uptake of 5.3% ID/g was observed, clearly delineating the tumor from other tissues. Unfortunately smaller molecules lend themselves less towards a SiFA labeling because of the difficulty of compensating for the SiFA lipophilicity. A small molecule such as a typical receptor ligand for brain imaging does not accept considerable structural modifications to adjust the SiFA lipophilicity without seriously compromising its binding properties to the target receptor. It is therefore unlikely that the SiFA labeling technique will grow into a staple for labeling molecules of small molecular weight. It is also true that all compounds reported so far have been only used in animal experiments. The SiFA methodology still has to prove its usefulness in a human clinical setting. This however requires extensive efforts and financial commitments from the academic research groups and it is hoped that the industry, which already showed interest in this labeling technique, will help transitioning this promising labeling technique to the clinic.

9. Conclusion

The SiFA methodology has grown over the years from a niche methodology to a broadly applied labeling strategy towards innovative [¹⁸F]-labeled radiopharmaceuticals for PET. SiFA radiolabeling procedures have been methodically studied and can be easily performed using either the SiFA leaving group approach or the SiFA-IE methodology. Moreover, those approaches are now well-established for a great variety of structurally distinct high affinity probes such as peptides, proteins, affibodies, and even small ligands. The practical simplicity and mild reaction conditions of the SiFA-IE strategy in particular represents a unique advantage in [¹⁸F]-labeling which, when applied in synergy with
the recently developed Munich drying method, helps meeting the requirements for a true kit-like $^{18}$F-labeling procedure.

**Abbreviations**

- PET: Positron emission tomography
- SiFA: Silicon-fluoride-acceptor
- IE: Isotopic exchange
- HPLC: High-performance liquid chromatography
- D$_2$ receptor: Dopamine receptor subtype D$_2$
- RCY: Radiochemical yield
- SPECT: Single-photon emission computed tomography
- GMP: Good Manufacturing Practice
- Nca: No-carrier-added
- DFT: Density functional theory
- BDE: Bond dissociation energy
- SPE: Solid phase extraction
- NALG: Nucleophile assisting leaving groups
- $S_N^2$: Nucleophilic substitution bimolecular
- BBN: Bombesin
- GRPR: Gastrin-releasing peptide receptor
- PEG: Polyethylene glycol
- SA: Specific radioactivity
- RSA: Rat serum albumin

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] C. Yoshida, A. B. Tsuji, H. Sudo et al., “Development of positron emission tomography probe of $^{64}$Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression,” Nuclear Medicine and Biology, vol. 38, no. 3, pp. 331–337, 2011.

[2] C. Wängler, B. Wängler, S. Lehner et al., “A universally applicable 68Ga-labeling technique for proteins,” Journal of Nuclear Medicine, vol. 52, no. 4, pp. 586–591, 2011.

[3] P. Szymański, T. Fraczek, M. Markowicz, and E. Mikiciuk-Olasik, "Development of copper based drugs, radiopharmaceuticals and medical materials," BioMetals, vol. 25, no. 6, pp. 1089–1112, 2012.

[4] B. M. Zeglis, J. L. Houghton, M. J. Evans, N. Viola-Villegas, and J. S. Lewis, "Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals," Inorganic Chemistry, vol. 53, no. 4, pp. 1880–1899, 2014.

[5] R. Schirrmacher, G. Bradtmöller, E. Schirrmacher et al., "18F-labeling of peptides by means of an organosilicon-based fluoride acceptor," Angewandte Chemie International Edition, vol. 45, no. 36, pp. 6047–6050, 2006.

[6] B. Wängler, G. Quandt, L. Iovkova et al., "Kit-like 18F-labeling of proteins: Synthesis of 4-(Di-tert-butyl[18F]fluorosilyl)benzenethiol (Si[18F]FA-SH) labeled rat serum albumin for blood pool imaging with PET," Bioconjugate Chemistry, vol. 20, no. 2, pp. 317–321, 2009.

[7] W. J. McBride, C. A. D’Souza, H. Karacay, R. M. Sharkey, and D. M. Goldenberg, "New lyophilized kit for rapid radiofluorination of peptides," Bioconjugate Chemistry, vol. 23, no. 3, pp. 538–547, 2012.

[8] E. Schirrmacher, B. Wängler, M. Cypryk et al., "synthesis of p-(Di-tert-butyl)[18F]fluorosilyl)benzaldehyde ([F-18]SiFA-A) with high specific activity by isotopic exchange: a convenient Labeling synthon for the F-18-labeling of n-amino-oxo derivatized peptides," Bioconjugate Chemistry, vol. 18, no. 6, pp. 2085–2089, 2007.

[9] A. Höhne, L. Mu, M. Honer et al., “Synthesis, $^{18}$F-labeling, and in vitro and in vivo studies of bombesin peptides modified with...
reactive synthon for radiofluorination of peptides and proteins," Applied Radiation and Isotopes, vol. 69, no. 2, pp. 410–414, 2011.

[39] A. Speranza, G. Orteocco, E. Castaldi, A. Nardelli, L. Pace, and M. Salvatore, “Fully automated synthesis procedure of 4-[18F]fluorobenzaldehyde by commercial synthesizer: aminooxi peptide labelling prosthetic group,” Applied Radiation and Isotopes, vol. 67, no. 9, pp. 1664–1669, 2009.

[40] D. Thonon, D. Goblet, E. Goukens et al., “Fully automated preparation and conjugation of N-succinimidyl 4-[(18F)F]fluorobenzoate ((18F)SF) with RGD peptide using a GE FASTTab synthesizer,” Molecular Imaging and Biology, vol. 13, no. 6, pp. 1088–1095, 2011.

[41] L. Iovkova, B. Wanger, A. Waeber et al., “SiFA-modified phenylalanine: a key compound for the efficient synthesis of 18F-labeled peptides,” European Journal of Inorganic Chemistry, no. 14, pp. 2238–2246, 2011.

[42] L. F. Tietze and K. Schmuck, “SiFA azide: a new building block for PET imaging using click chemistry,” Synlett, no. 12, pp. 1697–1700, 2011.

[43] A. P. Kostikov, J. Chin, K. Orchowski et al., “Oxalic acid supported Si-18F-radiofluorination: one-step radiosynthesis of N-succinimidyl 3-(Di-tert-butyl)[18F]fluorosilyl) benzoxa (((18F)SiFB) for protein labeling,” Bioconjugate Chemistry, vol. 23, no. 1, pp. 106–114, 2012.

[44] P. Rosa-Neto, B. Wanger, L. Iovkova et al., “[18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins,” ChemBioChem, vol. 10, no. 8, pp. 1321–1324, 2009.

[45] L. Iovkova, B. Wanger, E. Schirrmacher et al., “Para-functionalyzed aryl-di-tert-butylfluorosilanes as potential labeling synthons for 18F radiopharmaceuticals,” Chemistry, vol. 15, no. 9, pp. 2140–2147, 2009.

[46] E. Balentova, C. Collet, S. Lamandé-Langle et al., “Synthesis and hydrolytic stability of novel 3-[18F] fluoroothoxybis(l-methylethyl)silyl)propanamine-based prosthetic groups,” Journal of Fluorine Chemistry, vol. 132, no. 4, pp. 250–257, 2011.

[47] C. Wånger, B. Waser, A. Alke et al., “One-step 18F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET),” Bioconjugate Chemistry, vol. 21, no. 12, pp. 2289–2296, 2010.

[48] M. Schottelius, F. Rau, J. C. Reubi, M. Schweiger, and H. Wester, “Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydrate chemistry,” Bioconjugate Chemistry, vol. 16, no. 2, pp. 429–437, 2005.

[49] M. Schottelius, H. J. Wester, J. C. Reubi, R. Senekowski-Schmidtke, and M. Schweiger, “Improvement of pharmacokinetics of radioiodinated Tyr3-octreotide by conjugation with carbohydrates,” Bioconjugate Chemistry, vol. 13, no. 5, pp. 1021–1030, 2002.

[50] P. Antunes, M. Ginj, M. A. Walter, J. H. Chen, J. C. Reubi, and H. R. Maecke, “Influence of different spacers on the biological profile of a DOTA-somatostatin analogue,” Bioconjugate Chemistry, vol. 18, no. 1, pp. 84–92, 2007.

[51] C. Wånger, S. Niedermoser, J. Chin et al., “One-step 18F-labeling of peptides for positron emission tomography imaging using the SiFA methodology,” Nature Protocols, vol. 7, no. 11, pp. 1946–1955, 2012.

[52] E. Amigues, J. Schulz, M. Szlosek-Pinaud et al., “[18F]SiRiboRGD: from design and synthesis to the imaging of αvβ3 integrins in melanoma tumors,” ChemPlusChem, vol. 77, no. 5, pp. 345–349, 2012.

[53] R. Haubner, B. Kuhnast, C. Mang et al., “[18]F-galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates,” Bioconjugate Chemistry, vol. 15, no. 1, pp. 61–69, 2004.

[54] G. Vaidyanathan and M. R. Zalutsky, “Labeling proteins with fluorine-18 using N-succinimidyl 4-[(18F)F]fluorobenzoate,” Nuclear Medicine and Biology, vol. 19, no. 3, pp. 275–281, 1992.

[55] G. Vaidyanathan and M. R. Zalutsky, “Improved synthesis of N-succinimidyl 4-[(18F)F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment,” Bioconjugate Chemistry, vol. 5, no. 4, pp. 352–356, 1994.

[56] F. Wuest, M. Berndt, R. Bergmann, J. van den Hoff, and J. Pietzsch, “Synthesis and application of [18F]FDG-maleimideoxolone ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labelling of peptides and proteins,” Bioconjugate Chemistry, vol. 19, no. 6, pp. 1202–1210, 2008.

[57] Z. Miao, G. Ren, H. Liu, S. Qi, S. Wu, and Z. Cheng, “PET of EGFR expression with an 18F-labeled affibody molecule,” Journal of Nuclear Medicine, vol. 53, no. 7, pp. 1108–1112, 2012.

[58] A. P. Kostikov, J. Chin, K. Orchowski et al., “Synthesis of [18F]SiFB: a prosthetic group for direct protein radiolabeling for application in positron emission tomography,” Nature Protocols, vol. 7, no. 11, pp. 1956–1963, 2012.

[59] B. Wånger, A. P. Kostikov, S. Niedermoser et al., “Protein labeling with the labeling precursor [18F]SiFA-SH for positron emission tomography,” Nature Protocols, vol. 7, no. 11, pp. 1964–1969, 2012.

[60] M. Glaser, P. Iveson, S. Hoppmann et al., “Three methods for 18F labeling of the HER2-binding affibody molecules ZHER2,2893 including preclinical assessment,” Journal of Nuclear Medicine, vol. 54, no. 11, pp. 1981–1988, 2013.

[61] S. H. Wessmann, G. Henriksen, and H.-J. Wester, “Cryptate mediated nucleophilic 18F-fluorination without azeotropic drying,” NuklearMedizin, vol. 51, no. 1, pp. 1–8, 2012.

[62] P. Bohn, A. Deyine, R. Azzouz et al., “Design of silicon-based misomidoazole analogues and 18F-radiolabelling,” Nuclear Medicine and Biology, vol. 36, no. 8, pp. 895–905, 2009.

[63] Y. Joyard, R. Azzouz, L. Bischoff et al., “Synthesis of new 18F-radiolabeled silicon-based nitromidoazole compounds,” Bioorganic and Medicinal Chemistry, vol. 21, no. 13, pp. 3680–3688, 2013.

[64] J. Schulz, D. Vimont, T. Bordenave et al., “Silicon-based chemistry: an original and efficient one-step approach to [18F]-Nucleosides and [18F]-Oligonucleotides for PET imaging,” Chemistry, vol. 17, no. 11, pp. 3096–3100, 2011.

[65] L. Iovkova-Berends, C. Wånger, T. Zöller et al., “t-Bu,SiF-derivatized D2-receptor ligands: the first SiFA-containing small molecule radiotracers for target-specific PET-imaging,” Molecules, vol. 16, no. 9, pp. 7458–7479, 2011.

[66] P. P. Hazari, J. Schulz, D. Vimont et al., “A new SiF-dipropargyl glycerol scaffold as a versatile prosthetic group to design dimeric radioligands: synthesis of the [18F]BMPPSF tracer to image serotonin receptors,” ChemMedChem, vol. 8, pp. 1–14, 2013.
[67] M. J. Shashack, K. A. Cunningham, P. K. Seitz et al., “Synthesis and evaluation of dimeric derivatives of 5-HT 2A receptor (5-HT 2AR) antagonist M-100907,” ACS Chemical Neuroscience, vol. 2, no. 11, pp. 640–644, 2011.

[68] S. Niedermoser, C. Wängler, J. Chin et al., “Chemical and biological evaluation of new hydrophilic $^{18}$F SiFA-derivatized somatostatin analogues,” Journal of Nuclear Medicine, vol. 54, supplement 2, p. 60, 2013.

[69] S. K. Lindner, C. Michler, S. Leidner et al., “Synthesis, in vitro and in vivo evaluation of SiFA -tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography (PET),” Bioconjugate Chemistry, 2014.